Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,463.44 -5.86 (-0.11%) Dow
38,989.90 -122.26 (-0.31%) Nasdaq
17,765.95 +48.30 (+0.27%) Bitcoin USD
61,656.50 -251.62 (-0.41%) CMC Crypto 200
1,279.20 -4.58 (-0.36%)
ITCI Nov 2024 65.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:46PM EDT. Market open.
| Previous close | 11.90 |
| Open | 11.90 |
| Bid | 11.00 |
| Ask | 12.50 |
| Strike | 65.00 |
| Expiry date | 2024-11-15 |
| Day's range | 11.70 - 12.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 55 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.